Cosmo Pharmaceuticals

C43.F

Dublin, Ireland· Est. 1997

cosmopharmaceuticals.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

C43.F · Stock Price

EUR 83.50+30.00 (+56.07%)

Market Cap: $1.6B

Historical price data

Overview

Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.

GastroenterologyDermatology

Technology Platform

Proprietary MMX® (Multi Matrix System) technology, an oral, pH- and time-dependent drug delivery platform designed for targeted colonic release of active pharmaceutical ingredients, enhancing efficacy and safety.

Pipeline

4 drugs in pipeline

Drug	Indication	Stage
Methylene Blue MMX 25 mg modified release tablets	Colon Staining in Preparation for Colonoscopy	Phase 2
Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + ...	Diarrhea-predominant Irritable Bowel Syndrome	Phase 2
400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 12...	Infectious Diarrhoea	Phase 2
CB-03-10	Advanced Refractory Solid Tumors	Phase 1

Funding History

IPOUndisclosedUndisclosedJun 15, 2007

Opportunities

Near-term catalysts include regulatory approvals for Methylene Blue MMX® in colorectal cancer detection and CB-03-01 for acne, which could open significant new revenue streams.

The growing adoption of AI in endoscopy presents a high-growth opportunity for the GI Genius™ system to become a standard of care, enhancing the company's medtech footprint.

Risk Factors

Key risks include dependency on a limited number of licensing partners for major revenue, potential regulatory setbacks for late-stage pipeline assets, and intense competition in both the GI therapeutics and AI-medtech diagnostics spaces from larger, well-resourced companies.

Competitive Landscape

In GI therapeutics, Cosmo differentiates via targeted MMX® delivery against systemic biologics and older oral drugs. In diagnostics, its GI Genius™ AI system competes with similar products from major medtech players like Medtronic and Olympus. The company's strategy focuses on carving out specialized niches rather than direct head-to-head competition with broad-market giants.